Approximately 60 patients suffering breakthrough cancer pain to participate in clinical trial that compares fentanyl with inhaled medical cannabis.
Health Canada approval for next phase of vaporized cannabinoid drug clinical trial.
Clinical trial to start and finish by year end
Tetra’s PPP001 is currently in Phase 3, with the end goal being a DIN,” says Aphria CEO.
“Enormous opportunity” for relationship with Tetra, as supplier and shareholder.
TetraBioPharma is quickly advancing plans to commercialize its #cannabis-based drug and specially designed vaporizer to treat fibromyalgia after getting approval from the Independent Ethics Board.
Fibromyalgia patients using cannabis saw dramatic improvement and astonished physicians w/ comments like “This is a miraculous treatment” & “I returned to same person I was before”
Heath Canada decision to reclassify, to a Phase Two medical device, the @TetraBioPharma inhalation pipe for cannabis medication means that patients suffering cancer pain may soon be able to claim the cost through their private and public insurance plans.
@TetraBioPharma today announced a new CBD supply agreement with Alberta-based True North Cannabis.
True North will supply Tetra with high-quality, competitively priced CBD
TetraBioPharma plans to bring international marketing and development
A cannabis-derived drug that could reduce opioid fentanyl use for breakthrough cancer pain is one step closer thanks to Health Canada approval that will allow a clinical trial to begin in October.